AB 928 CAS 2239273-34-6

Introduction：Basic information about AB 928 CAS 2239273-34-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

AB 928 Basic information

• Product Name: AB 928
• Synonyms: AB 928);AB928(AB-928;3-(2-amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile;Benzonitrile, 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1H-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methyl-;Etrumadenant (AB928);AB928,inhibit,AB-928,AB 928,P1 receptor,Adenosine Receptor,Inhibitor;3-[2-Amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile;AB928, 10 mM in DMSO
• CAS: 2239273-34-6
• MF: C23H22N8O
• MW: 426.47
• Product Categories: APIs
• Mol File: 2239273-34-6.mol

AB 928 Chemical Properties

• Boiling point: 723.4±70.0 °C(Predicted)
• density: 1.34±0.1 g/cm3(Predicted)
• storage temp.: Store at -20°C
• solubility: DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
• form: A crystalline solid
• pka: 13.33±0.29(Predicted)
• color: Off-white to light yellow

AB 928 Usage And Synthesis

Uses

Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities[1][2].

in vivo

Concurrent treatment with Etrumadenant and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of Etrumadenant and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. Etrumadenant increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors^[2].

References

[1] Seitz L, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019 Aug;37(4):711-721. DOI:10.1007/s10637-018-0706-6
[2] Daniel DiRenzo, et al. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression [abstract].